As shown in Figure 3, letrozole has an inhibitory effect on angiogenesis, therefore it is expected that patients with ERα-positive recurrent ovarian cancers are candidates of letrozole administration alone or in combination with bevacizumab, a drug that targets molecules involved in angiogenesis. Here, ESR1 is linked to ovarian cancer.